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We recently showed that Sl, a sequence-scrambled form of CD4 CDR3-related synthetic peptide, has more potent inhibitory activities on HIV-l 
replication and HIV-l-induced syncytium formation than the original form. In this study, a series of derivatives of Sl were synthesized and their 
anti-HIV-l activities were evaluated. A o-isomer was as potent as Sl, and a homodimer was lo- to l&fold more potent than Sl. The increased 
antiviral activity of the dimer peptide was related to a-helix formation, as detected by circular dichroism. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
The binding of human immunodeficiency virus type 
1 (HIV-l) envelope glycoprotein, gp120, to the cellular 
receptor CD4 is the first step in the infection of CD4’ 
cells by HIV-l [l-3]. The CD4 binding causes confor- 
mational changes in gp120 and leads to the dissociation 
of gp120 from the virus [4-61. Some synthetic peptides 
derived from the CD4 region, corresponding to the im- 
munoglobulin third complementarity-determining re- 
gion (CDR3) or its adjacent region, which show inhib- 
itory effects on HIV-l infection and HIV-l-induced 
syncytium formation [7-91, also induce the gp120 shed- 
ding, as well as soluble CD4 [lO,l 11. 
2.1. Synthesis of CD4 CDIU-related peptides 
Structure-activity analysis of these CD4 CDR3-re- 
lated peptides showed that a scrambled peptide, Sl, 
altered in the amino acid sequence of the CD4 CDR3- 
related peptide CD4(6&92) but not in overall composi- 
tion, has stronger anti-HIV-l activity than the original 
native sequence [12]. In this study, we examined the 
effect of the Sl peptide upon anti-HIV-l activities after 
further modification, including D-isomerization, dimeri- 
zation and conjugation with lipophilic substances uch 
as phospholipids. The results indicated that the dimer 
derivative had increased activities at micromolar con- 
centrations. 
CD4 CDR3-related peptides (Table I) were synthesized on a Milli- 
Gen/Biosearch 9050 peptide synthesizer using Fmoc chemistry [13]. 
The peptides were purified by reverse-phase HPLC (> 95% purity), 
then characterized by amino acid analysis and fast atom bombard- 
ment mass spectrometry: CD4(6692), m/z 3,316.32 (calculated 
3,316.74); Sl, m/z 3,316.79; Sl-D, m/z 3,316.46; CSl, m/z 3,419.33 
(calculated 3,419.78); SSl-C, m/z 2,257.71 (calculated 2,257&l). Lyo- 
philized peptides were stored desiccated at - 20°C. The homodimer 
peptide (CSl (dimer)) was prepared by air-oxidizing the CSl (Sl 
analogue containing N-terminal cysteine) in 50 mM sodium phosphate 
buffer (pH 7.2) at a concentration of 2 mg/ml for 6 h at room temper- 
ature. HPLC analysis confirmed the quantitative formation of the 
dimer peptide. The peptide-phospholipid conjugate (Sl-PE) was pre- 
pared by derivatizing egg yolk phosphatidylethanolamine (PE) with 
N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) [14] and cou- 
pling the thiolated PE with CSl at a molar ratio of 1:l. 
2.2. Cells and viruses 
Ml0 [15], a clonal cell line of MT-4, and MOLT-4 clone No. 8 [16] 
cells were maintained in RPMI-1640 medium supplemented with 10% 
(v/v) heat-inactivated fetal bovine serum, as described previously [12]. 
The conditioned medium of MOLT-4 cells persistently infected with 
HIV-l HT,_v.,,,B (MOLT-WHIV-1) was used as a virus inoculum. 
2.3. HIV-I infectivity assay 
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Abbreviations: HIV-l, human immunodeficiency virus type 1; CDR, 
complementarity-determining re ion; CD, circular dichroism; TCID, 
tissue culture infectious dose; PE, phosphatidylethanolamine; CPE, 
cytopathic effect. 
The ability of CD4 CDR3-related peptides to reduce viral infectivity 
(TCID,dml) was tested as described previously [9]. Briefly, Ml0 cells 
in 96-well microplates (5 x 10“ cells/well) were cultured with serial 
IO-fold dilutions of an HIV-l inoculum which had been incubated 
with peptides for 30 min at 37°C. To determine the dose-dependence 
of the drugs, Ml0 cells were infected with HIV-l (5 x lo3 TCID,,,) 
after an incubation with serial 4-fold dilutions of peptides for 30 min 
at 37°C. After incubation for 4 days at 37°C the cells were fixed with 
cold acetone. HIV-l antigen expression in the cells was detected by 
indirect immunofluorescence using serum from an HIV-I-seropositive 
patient. 
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2.4. Cytopathic effect (CPE) assay without preincubation of HIV-l 
with peptides 
Ml0 cells in 96-well microplates were mixed with HIV-l (100 
TCID,,) and CD4 CDR3-related peptides in duplicate (2.5 x lo4 cells/ 
well, 100 pl), then incubated for 6 days at 37’C. On day 3, 100 ~1 of 
fresh medium containing appropriate concentrations of peptides was 
added to each well. The ability of the peptides to inhibit virus-induced 
CPE in M 10 cells was evaluated by the viable cell number determined 
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetr~olium bro ide 
(MTT) method [17]. 
2.5. Assay of HIV-l-induced syncytium formation 
MOLT-I/HIV-l cells (5 x 10’) in 96-well microplates were incu- 
bated with CD4 CDR3-related peptides for 30 min at 37’C, then 
co-cultured with MOLT-4 clone No. 8 cells (5 x 104) for 24 h at 37°C 
in triplicate, as described [12]. The number of syncytia was counted 
microscopically and the relative syncytium formation (%) to the un- 
treated control was calculated. 
2.6. Cytotoxicity assay 
Cells in 96-well microplates (5 x 10“ cells/well) were incubated in the 
presence or absence of CD4 CDR3-related peptides for 3 days at 37°C 
in duplicate, and the cell viability was determined by the MTT method. 
2.7. Assay of p24 antigen capture 
The amount of ~24 antigen in the conditioned media of MOLT-W 
HIV-l cells was determined using a commercial ELISA kit. 
2.8. Circular dichroism (CD) analysis 
CD spectra of CD4 CDR3-related peptides at = 0.1 mg/ml in 10 mM 
sodium phosphate buffer, pH 7.2, were measured in a 0.2 cm- path- 
length cell on a Jasco J-720 spectropolarimeter. Temperature scans 
were taken at a slope of 50°C/h. Secondary structure contents were 
estimated using the program, J-700/98 SSE-338 Ver. l.OOe (Jasco), as 
described [12]. 
2.9. Chemical reagents 
Reagents were obtained commercially: Fmoc-n/L-amino acids from 
Watanabe Chemical Industries (Hiroshima, Japan); egg yolk PE and 
MTT from Sigma (St. Louis, MO); SPDP from Pierce (Rockford, IL); 
FITC-conjugated rabbit anti-human IgG from Dakopatts A/S 
(Copenhagen, Denmark); ~24 antigen capture ELISA kit from Amer- 
ican Bio-Technologies (Cambridge, MA). 
3. RESULTS 
3.1. Anti-HIV-l activity of Sl-derived peptides 
CD4 CDR3-related peptide derivatives were first 
screened for their inhibitory effect on HIV-l infectivity 
by measuring residual viral infectivity after incubating 
the HIV-I inoculum with the peptides for 30 min at 
37°C (Table II). Both Sl-D (o-isomer of Sl) and Sl 
Table I 







Bold residues represent o-amino acids. Cb, S-benzyl-Lcysteine. 
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Table II 
Inhibitory effect of CD4 CDR3-related peptides on HIV-l infectivity 
Peptide Cont. (mg/ml) TCID$ml” 
No peptide loss 
CD4(66-92) 1 1o35 
Sl 1 lozO 
Sl-D 1 10’ 66 
CSl (dimer) 1 c1o’5 
Sl-PE 0.25 c1o’5 
SSl-c 0.5 1oa5 
a HIV-I was incubated for 30 min with indicated concentrations of 
peptides at 37”C, and residual infectivity (TCID,,,/ml) was deter- 
mined in Ml0 cells. 
(L-isomer) showed strong inhibitory activity against 
HIV- 1. In addition, air-oxidized CSl (dimer) and Sl -PE 
(phospholipid conjugate of CSl), completely blocked 
HIV-l infectivity in this assay system. SSl-C, which 
contains about two-thirds of the C-terminal portion of 
Sl and the N-terminal serine, was less active. 
We then examined the dose-dependence and cytotox- 
icity of the peptides. As shown in Fig. 1, Sl-D was as 
potent as Sl, and CSl (dimer) was lo- to 15fold more 
active than Sl in inhibiting viral infection in Ml0 cells, 
as evidenced by immunofluorescence. The doses re- 
quired for a 50% reduction of viral antigen expression 
(IC,,) were 205 and 17 ,@rnl for Sl-D and CSl (dimer), 
respectively (Table III). When cells were infected with 
HIV-l without preincubating the virus with peptides, 
slightly higher doses were required for similar inhibition 
in the CPE assay; the IC& were 450 and 40 &ml for 
Sl-D and CSl (dimer), respectively (Table III). Under 
the same assay conditions, Sl-PE had an ICsO of 25 
pg/ml, although toxicity to Ml0 cells appeared, namely, 
a CCsO (dose for 50% cytotoxicity) of 240 ,&ml. Other 
peptides showed no cytotoxicity even at 1,00 &ml. 
The peptides also inhibited HIV- 1 -induced syncytium 
formation. Under our assay conditions, MOLT-WHIV- 
1 cells were first incubated with the peptides for 30 min 
at 37°C then co-cultured with uninfected MOLT-4 
clone No. 8 cells. The inhibition of syncytium formation 
between the infected and uninfected T cells by Sl-de- 
rived peptides was dose-dependent. The IC,, values 
were 80,56 and 4.4&ml for Sl, Sl-D and CSl (dimer), 
respectively (Table III). 
3.2. Effect of CDI-relatedpeptides on HIV-l production 
by persistently HIV-l-infected cells 
CD4(66-92), Sl and Sl-derived peptides were exam- 
ined for their inhibitory effects on the HIV-l production 
from MOLT-4/HIV-1 cells. MOLT-4/HIV-1 cells at 
5 x 105/ml were cultured for 3 days in the presence of the 
peptides. None of the peptides were cytotoxic (Fig. 2). 
However, the ELISA assay of p24 antigen in the condi- 
tioned medium revealed no significant effect of the pep- 
tides upon HIV-l production. This indicates that these 
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Fig. 1. Dose-dependent inhibitory effect of Sl-derived peptides on the 
expression of HIV-l-specific antigen in Ml0 cells. Ml0 cells (5 x 10“) 
were cultured with HIV-l (5 x 10” TCID,) which had been preincu- 
bated with CD4 CDR3-related peptides for 30 min at 37°C. After 4 
days, HIV-l antigen-positive cells were identified by indirect 
immunofluorescence. 
peptides block HIV-l infectivity and syncytium forma- 
tion but lack the ability to prevent viral replication in, 
or release from, already infected cells. 
3.3. Structure analysis of CDI-related peptides by CD 
The structures of Sl -derived peptides in solution were 
analyzed by CD. Fig. 3A shows a comparison of the 
ultra-violet CD spectra of Sl , Sl-D and CSl (dimer) in 
10 mM phosphate buffer, pH 7.2, at 37°C. The CD 
spectrum of Sl -D was the mirror image of that of Sl, 
indicating that S 1 -D fully retains the o-amino acid con- 
figuration in solution. The CD spectrum of CSl (dimer) 
was similar to that of Sl, but the negative CD intensity 
at a shoulder peak around 218-222 nm was stronger in 
CSl than in Sl . The CD spectrum of CSl (dimer) exhib- 
ited another negative peak at 206 nm and a strong pos- 
itive peak at 192 nm. These results are indicative of 
helix-helix interactions [181 in the dimer CSl . We then 
examined the effect of temperature on the CD intensity 
at 220 nm, at which a-helix-to-random coil transitions 
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Fig. 2. Effect of CD4 CDR3-related peptides on persistently HIV-l- 
infected cells. MOLT-4/HIV-1 cells were incubated without or with 
the peptides at 1 mg/ml for 3 days at 37°C. Cell growth (open bars) 
was determined by the MTT method, while HIV-l p24 antigen in the 
conditioned medium (closed bars) was measured by ELISA. 
profiles of Sl and CSI (dimer) measured by CD at 220 
nm. The negative CD intensity of the dimer CSl was 
progressively reduced with increasing temperature, 
whereas no apparent change in Sl, coinciding with a 
previous observation that p-sheets or random coils 
without substantial helix conformations, were detected 
in S 1 in solution [ 121. These results indicate the presence 
of a temperature-sensitive s condary structure, that is, 
an a-helix in the disulfide-crosslinked CSl, but not in 
Sl . The estimated helical contents of dimer CSl and Sl 
(11.8% and 2.0%, respectively), from their CD spectra 
based on the method of Yang et al. [20], support this 
conclusion. Thus, it is noteworthy that the structure of 
dimer CSl at 37°C could be stabilized by this a-helix 
formation, contributing to its increased anti-HIV-l ac- 
tivities. 
4. DISCUSSION 
The o-isomer of Sl (Sl-D), fully retaining n-amino 
acid configuration in solution, was as potent as Sl in 
inhibiting HIV-l infection and HIV-l-induced 
syncytium formation. This suggests that there are no 
configurational restraints upon its antiviral activity. 
Table III 
Summary of anti-HIV-l activities and cytotoxicity of CD4 CDR3-related peptides 




Preincubation” No preincubation 
CD4(6692) 990 > 1,000 1,000 
Sl 190 300 1,000 
Sl-D 205 450 l,W 
CSl (dimer) 17 40 1,000 
Sl-PE NDb 25 240 
a HIV-l was incubated with peptides for 30 min at 37°C before being added to Ml0 cells. 
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Fig. 3. CD spectra of CD4 CDR3-related peptides. (A) The CD spectra of Sl, Sl-D and CSl (dimer) at 37°C. CD intensity is given in millidegrees 
(mdeg). (B) The effect of temperature on the CD intensity of Sl and CSl (dimer) measured at 220 nm. 
Several groups have reported that CD4 CDR3-related 
peptide derivatives and polyanionic compounds, such 
as sulfated polysaccharides, specifically bind to the 
gp120 V3 loop [21-231. We also found that Sl inhibits 
the binding of anti-V3 monoclonal antibodies to the V3 
loop, even at a lower concentration than that showing 
antiviral activities [l 11. Acidic amino acid residues are 
clustered at the N-terminus portion in Sl, while the 
dispersed form of the acidic residues has greatly reduced 
antiviral activities [12]. The V3 loop of gp120 contains 
a high concentration of positively charged residues 
which are highly conserved among divergent HIV-l iso- 
lates [22,24]. Therefore, the anti-HIV-l activities of Sl 
and Sl-derived peptides could be the result of direct 
electrostatic interactions between the polyanionic re- 
gion in the peptides and the cationic cluster present in 
the V3 loop. 
Another important finding in the present study was 
the increased anti-HIV-l activity of the dimer analogue 
of Sl . The homodimer CS 1 peptide exerted antiviral 
activities with an I& of 4.417 &ml (0.625 PM) 
when preincubated with HIV-l or HIV-l-infected cells 
before contact with uninfected cells (Table III). CD 
analysis (Fig. 3A) indicated that an a-helical conforma- 
tion was present in the secondary structure of the dimer 
peptide at a ratio of 12% at 37°C. No thermal unfolding 
was detected in the dimer peptide at temperatures below 
40°C (Fig. 3B). These results suggest hat this modifica- 
tion stabilized the secondary structure of the peptide by 
cx-helix formation, probably enabling the stable interac- 
tion with the viral envelope glycoprotein. These results 
appear consistent with the previous observation that 
disulfide bridging of a synthetic peptide derived from 
gp41 (amino acid residues 558-595) stabilized the pep- 
tide structure and increased its antiviral activity [25]. 
Thus, the increased activities of CD4 CDR3-related 
peptide derivatives examined here may provide an alter- 
native anti-HIV-l approach by targeting the gp120 V3 
loop. 
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